Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer

Docetaxel (DTX) chemotherapy remains a standard-of-care for metastatic castration-resistant prostate cancer (CRPC). DTX modestly increases survival, yet results in frequent occurrence of side-effects and resistant disease. An alternate chemotherapy with greater efficacy and minimal side-effects is n...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Babcook, Melissa A., Shukla, Sanjeev, Fu, Pingfu, Vazquez, Edwin J., Puchowicz, Michelle A., Molter, Joseph P., Oak, Christine Z., MacLennan, Gregory T., Flask, Chris A., Lindner, Daniel J., Parker, Yvonne, Daneshgari, Firouz, Gupta, Sanjay
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185215/
https://ncbi.nlm.nih.gov/pubmed/25122066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0451
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller